Omeros: PDUFA Delay Presents An Opportunity
I left off Omeros (OMER) in February 2019. At that time, it was running a phase 3 trial in HSCT-TMA for OMS721/narsoplimab, and was in ongoing discussions with the FDA about whether it could abandon historical controls or comparative data and simply look…
